GlassScriptPhysician profile
Christina E Cano Gonzalez
NPI 1548267180
$5,111.14
in general payments reported to CMS, 2019-2025
26 companies · $998 in 2025
The $998 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $857 · 2020: $450 · 2021: $566 · 2022: $214 · 2023: $677 · 2024: $1,349 · 2025: $998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,024.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,511.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,424.28 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $444.02 | 2019-2025 | Farxiga, Breztri |
| Amarin Pharma, INC. | $401.52 | 2019-2021 | |
| Amgen INC. | $202.90 | 2019-2025 | Repatha, Otezla, Repatha |
| Impulse Dynamics (USA) INC. | $149.92 | 2024 | Optimizer |
| Astellas Pharma US INC | $115.74 | 2024-2025 | Veozah |
| Pfizer INC. | $108.96 | 2019-2025 | |
| Mylan Specialty L.P. | $104.52 | 2019 | |
| Glaxosmithkline, LLC. | $95.08 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.00 | 2024-2025 | Jardiance, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $76.27 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $65.47 | 2020-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $52.74 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $37.34 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $37.07 | 2024 | Korlym |
| Abbvie INC. | $27.75 | 2025 | |
| Novartis Pharmaceuticals Corporation | $25.75 | 2023 | |
| Biosense Webster, INC. | $24.33 | 2024 | Carto 3 |
| Phadia US INC. | $22.65 | 2024 | Immunocap |
| Amag Pharmaceuticals, INC. | $19.23 | 2019 | |
| Abbott Laboratories | $18.45 | 2022 | |
| Idorsia Pharmaceuticals US INC | $18.29 | 2023 | Quviviq |
| Exact Sciences Corporation | $15.66 | 2023 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $14.76 | 2021 | |
| Si-Bone, INC. | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Cano Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.